EOM 1352: Fri 7 June 2024, 11:36

Current Edition

ramusmedical
news

Multiple Sclerosis Drug Slows Brain Shrinkage

A new brain imaging clinical trial funded by the National Institutes of Health (NIH) has showed that multiple sclerosis drug ibudilast was better than a placebo at sl...
Continue Reading →
news

Pfizer and Astellas amend clinical research protocols for two phase 3 trials of enzalutamide in patients with hormone-sensitive prostate cancer

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registr...
Continue Reading →
Europe

Cannabis extract helps reset brain function in psychosis

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with ...
Continue Reading →
Europe

Medicine24: the issue of infections in people who inject drugs

The Royal College of Physicians and Surgeons of Glasgow is to host a speaker at their flagship conference, Medicine24 who will talk about infections in people who inj...
Continue Reading →
news

Cleveland clinic-led trial shows unprecedented slowing in progressive multiple sclerosis

Sunday, September 2, 2018: A promising drug slowed brain shrinkage in progressive multiple sclerosis (MS) by nearly half, according to new research led by Cleveland C...
Continue Reading →
news

CRF Health Partners Innovative US Biotech with TrialMax® eCOA Solution for Phase III Prostate Oncology Study

Plymouth Meeting, PA – August 30, 2018: CRF Health, the leading provider of patient-centered eSource technology solutions for the life sciences industry, today announ...
Continue Reading →
Europe

Nanobiotix half year results for the six months ended June 30, 2018

Major milestones achieved with the success of Soft Tissue Sarcoma phase III clinical trial with first-in-class NBTXR3 product Overall expenses according to pla...
Continue Reading →
Europe

Minoryx Therapeutics announces dosing of first US patient in phase 2/3 clinical study of MIN-102 (ADVANCE)

ADVANCE trial recruitment is progressing rapidly in Europe with over 50 percent X-ALD patients enrolled  Mataró, Barcelona, Spain, September 5, 2018- Minoryx Therapeu...
Continue Reading →
Europe

Thrombolytic Science Initiates Phase 2 Clinical Trial of its Novel Treatment Regimen for Ischemic Stroke

Study Seeks to Confirm Efficacy and Safety of Next-generation Clot-dissolving Therapy Consisting of Low-dose tPA and HisproUK Cambridge, Mass., USA, September 05, 201...
Continue Reading →
Europe

Novartis receives EC approval for Kymriah to treat two cancers

The European Commission (EC) has granted approval for Novartis’ Kymriah to treat patients with B-cell acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lym...
Continue Reading →
Quotient